Chongqing Taiji Industry (600129.SH): Dexmedetomidine Injection passed the consistency evaluation of generic drugs.

Chongqing Taiji Industry (600129.SH) announced that its holding subsidiary Southwest Pharmaceutical Co., Ltd. (hereinafter referred to as Southwest Pharmaceutical) has received the "Drug Supplementary Application Approval Letter" from the National Medical Products Administration for Digoxin Injection (specification: 2ml:0.5mg). Southwest Pharmaceutical's Digoxin Injection has passed the generic drug quality and efficacy consistency evaluation. This product can be used to treat mild to moderate heart failure in adults, increase myocardial contractility in pediatric patients with heart failure, control ventricular rate in atrial fibrillation and atrial flutter patients with rapid heart rate, and treat supraventricular tachycardia. Digoxin Injection (2ml:0.5mg) is a Category A drug in the National Medical Insurance Catalog (2025 edition) and has been included in the 2026 edition of the National Essential Medicines List. It is also recommended in domestic and foreign clinical guidelines and expert consensus for heart failure and atrial fibrillation. As of the date of this announcement, according to the database of the National Medical Products Administration, a total of 17 companies in China have production permits for Digoxin Injection, and 13 of them have passed the generic drug consistency evaluation.